Почетна › Trostruko negativni rak dojke › Džordžija
Kliničke studije za Trostruko negativni rak dojke u državi Džordžija
25 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Džordžija.
Gradovi u državi Džordžija
Zvanični tekst studije (na engleskom)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University Cancer & Blood Center, LLC ( Site 0023), Athens
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Emory Winship Cancer Institute, Atlanta
- Augusta University, Augusta
Тражи се учесникФаза 1
Узраст 19 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06586957A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- University Cancer & Blood Center, Athens
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06150664Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University Cancer & Blood Center, LLC., Athens
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472Study of XB010 in Subjects With Solid Tumors
- Winship Cancer Institute, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06545331A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT05570253Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT05846789ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 31. 8. 2026. · NCT06460298A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Winship Cancer Institute / Emory University, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 6. 2026. · NCT05768932A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Georgia Cancer Center, Augusta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT04300556Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Emory University Hospital, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 6. 2026. · NCT05741164Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 18 и старији · Жене · Ажурирано 7. 5. 2026. · NCT05877859I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT01042379High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Emory University Hospital/Winship Cancer Institute, Atlanta
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 17. 4. 2026. · NCT06492759Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
- Emory University, Winship Cancer Institute, Atlanta
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 2. 2026. · NCT02926690A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Winship Cancer Institute - Emory University, Atlanta
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 1. 2026. · NCT06926920Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- и још 1
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 1. 2026. · NCT06324240A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Columbus Regional Research Institute, LLC, Columbus
Тражи се учесникФаза 3
Узраст од 18 до 65 · Жене · Ажурирано 21. 3. 2025. · NCT03671044Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.